Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine

Hana Kovárová*, Marián Hajdúch, Gabriela Koínková, Petr Halada, Stanislava Krupiková, Adam Gouldsworthy, Nikolai Zhelev, Miroslav Strnad

*Corresponding author for this work

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The aim of this study was to use two-dimensional electrophoresis (2-DE) coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin-derived cyclin-dependent kinase inhibitor (CDKI). Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 h treated BOH cells while the second is represented by the 0 and 24 h control untreated cells and the 6 h BOH-exposed CEM lymphoblasts. Discriminant protein spots differentially expressed in the BOH-treated CEM cells were selected for identification by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS) or electrospray ionization-tandem MS (ESI-MS/MS). Five of the selected protein spots were unequivocally identified as α-enolase, triosephosphate isomerase, eukaryotic initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins, all significantly downregulated in CEM T-lymphoblast leukemia in the course of BOH treatment, are known to play an important role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton rearrangement. These results indicate that the cellular effects of olomoucine-derived CDKIs are not dependent on their ability to inhibit CDKs and could be mediated by several factors such as a decrease in protein synthesis and/or glycolysis which in turn diminishes the ability of cancer cells to function.

Original languageEnglish
Pages (from-to)3757-3764
Number of pages8
JournalElectrophoresis
Volume21
Issue number17
DOIs
Publication statusPublished - Nov 2000
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinases
Proteomics
Proteins
Glycolysis
rho Guanine Nucleotide Dissociation Inhibitor alpha
Triose-Phosphate Isomerase
Eukaryotic Initiation Factors
Cells
Phosphopyruvate Hydratase
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Protein Biosynthesis
Electrospray ionization
Principal Component Analysis
Cytoskeleton
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Biosynthesis
Electrophoresis
olomoucine
bohemine
Leukemia

Cite this

Kovárová, Hana ; Hajdúch, Marián ; Koínková, Gabriela ; Halada, Petr ; Krupiková, Stanislava ; Gouldsworthy, Adam ; Zhelev, Nikolai ; Strnad, Miroslav. / Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. In: Electrophoresis. 2000 ; Vol. 21, No. 17. pp. 3757-3764.
@article{6360476818a049c58bff286744cee844,
title = "Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine",
abstract = "The aim of this study was to use two-dimensional electrophoresis (2-DE) coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin-derived cyclin-dependent kinase inhibitor (CDKI). Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 h treated BOH cells while the second is represented by the 0 and 24 h control untreated cells and the 6 h BOH-exposed CEM lymphoblasts. Discriminant protein spots differentially expressed in the BOH-treated CEM cells were selected for identification by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS) or electrospray ionization-tandem MS (ESI-MS/MS). Five of the selected protein spots were unequivocally identified as α-enolase, triosephosphate isomerase, eukaryotic initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins, all significantly downregulated in CEM T-lymphoblast leukemia in the course of BOH treatment, are known to play an important role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton rearrangement. These results indicate that the cellular effects of olomoucine-derived CDKIs are not dependent on their ability to inhibit CDKs and could be mediated by several factors such as a decrease in protein synthesis and/or glycolysis which in turn diminishes the ability of cancer cells to function.",
author = "Hana Kov{\'a}rov{\'a} and Mari{\'a}n Hajd{\'u}ch and Gabriela Ko{\'i}nkov{\'a} and Petr Halada and Stanislava Krupikov{\'a} and Adam Gouldsworthy and Nikolai Zhelev and Miroslav Strnad",
year = "2000",
month = "11",
doi = "10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X",
language = "English",
volume = "21",
pages = "3757--3764",
journal = "Electrophoresis",
issn = "0173-0835",
publisher = "Wiley-VCH Verlag",
number = "17",

}

Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. / Kovárová, Hana; Hajdúch, Marián; Koínková, Gabriela; Halada, Petr; Krupiková, Stanislava; Gouldsworthy, Adam; Zhelev, Nikolai; Strnad, Miroslav.

In: Electrophoresis, Vol. 21, No. 17, 11.2000, p. 3757-3764.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine

AU - Kovárová, Hana

AU - Hajdúch, Marián

AU - Koínková, Gabriela

AU - Halada, Petr

AU - Krupiková, Stanislava

AU - Gouldsworthy, Adam

AU - Zhelev, Nikolai

AU - Strnad, Miroslav

PY - 2000/11

Y1 - 2000/11

N2 - The aim of this study was to use two-dimensional electrophoresis (2-DE) coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin-derived cyclin-dependent kinase inhibitor (CDKI). Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 h treated BOH cells while the second is represented by the 0 and 24 h control untreated cells and the 6 h BOH-exposed CEM lymphoblasts. Discriminant protein spots differentially expressed in the BOH-treated CEM cells were selected for identification by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS) or electrospray ionization-tandem MS (ESI-MS/MS). Five of the selected protein spots were unequivocally identified as α-enolase, triosephosphate isomerase, eukaryotic initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins, all significantly downregulated in CEM T-lymphoblast leukemia in the course of BOH treatment, are known to play an important role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton rearrangement. These results indicate that the cellular effects of olomoucine-derived CDKIs are not dependent on their ability to inhibit CDKs and could be mediated by several factors such as a decrease in protein synthesis and/or glycolysis which in turn diminishes the ability of cancer cells to function.

AB - The aim of this study was to use two-dimensional electrophoresis (2-DE) coupled with multivariate principal component analysis (PCA) to characterize the quantitative changes in the protein composition of the CEM T-lymphoblastic leukemia cell line after treatment with bohemine (BOH), a synthetic olomoucin-derived cyclin-dependent kinase inhibitor (CDKI). Cell classification, reflecting protein patterns, clearly distinguished two main groups: one group consists of 9, 12 and 24 h treated BOH cells while the second is represented by the 0 and 24 h control untreated cells and the 6 h BOH-exposed CEM lymphoblasts. Discriminant protein spots differentially expressed in the BOH-treated CEM cells were selected for identification by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS) or electrospray ionization-tandem MS (ESI-MS/MS). Five of the selected protein spots were unequivocally identified as α-enolase, triosephosphate isomerase, eukaryotic initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins, all significantly downregulated in CEM T-lymphoblast leukemia in the course of BOH treatment, are known to play an important role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton rearrangement. These results indicate that the cellular effects of olomoucine-derived CDKIs are not dependent on their ability to inhibit CDKs and could be mediated by several factors such as a decrease in protein synthesis and/or glycolysis which in turn diminishes the ability of cancer cells to function.

U2 - 10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X

DO - 10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X

M3 - Article

VL - 21

SP - 3757

EP - 3764

JO - Electrophoresis

JF - Electrophoresis

SN - 0173-0835

IS - 17

ER -